GlassScriptPhysician profile
Jack I Kurtz
NPI 1114374873
$4,445.15
in general payments reported to CMS, 2019-2025
32 companies · $2,313 in 2025
The $2,313 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $124 · 2022: $162 · 2023: $287 · 2024: $1,434 · 2025: $2,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $627.29 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $390.89 | 2024-2025 | Onpattro, Amvuttra |
| Bridgebio Pharma, INC. | $386.22 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $327.83 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $308.57 | 2024-2025 | |
| Heartflow, INC. | $285.35 | 2025 | |
| Merck Sharp & Dohme LLC | $237.55 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $233.24 | 2021-2025 | |
| Scpharmaceuticals INC. | $214.49 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.20 | 2019-2025 | Jardiance |
| Amgen INC. | $198.70 | 2021-2025 | Repatha, Repatha |
| Atricure, INC. | $185.38 | 2023-2024 | |
| Abbott Laboratories | $125.80 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $113.73 | 2024-2025 | Wegovy |
| Cvrx, INC. | $95.07 | 2024-2025 | Barostim Neo System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $69.56 | 2024-2025 | Tyvaso, Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $61.62 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $52.80 | 2024 | Arcalyst |
| Medtronic, INC. | $48.62 | 2025 | Symplicity G3 |
| Actelion Pharmaceuticals US, INC. | $46.27 | 2024-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $34.59 | 2024 | Xarelto |
| Biotronik INC. | $32.60 | 2025 | Biomonitor |
| Impulse Dynamics (USA) INC. | $32.01 | 2025 | Optimizer |
| Lantheus Medical Imaging, INC. | $21.85 | 2021 | |
| Globus Medical, INC. | $19.49 | 2025 | Senza |
| Terumo Medical Corporation | $18.66 | 2025 | Metacross Otw, Glidewire, Progreat |
| Ionis Pharmaceuticals, INC. | $18.62 | 2025 | Tryngolza |
| Abiomed | $15.68 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2025 | |
| Chiesi USA, INC. | $11.76 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3.54 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Kurtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.